SCHEMBL1775874

SCHEMBL1775874

CN1CCN(c2cc(N3CCCC3)ncn2)CC1

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 10/20 0.64
HRH3 Q9Y5N1 2/20 0.58
HRH2 P25021 1/20 0.55
CYP1A2 P05177 5/20 0.54
ALDH1A1 P00352 3/20 0.53
HSD17B10 Q99714 2/20 0.53
ALOX15 P16050 2/20 0.53
KDM4E B2RXH2 1/20 0.53
GLA P06280 1/20 0.53
MAPT P10636 1/20 0.53
HPGD P15428 1/20 0.53
CYP2C19 P33261 1/20 0.53
CYP2C9 P11712 1/20 0.51
TSHR P16473 1/20 0.51
MAPK1 P28482 1/20 0.51
HTR3A P46098 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24319168 0.94 HRH4 (0.65) HRH4HRH3HRH2CYP1A2ALDH1A1
SCHEMBL19548104 0.85 SMN1; SMN2 (0.61) HRH4ALDH1A1TSHR
SCHEMBL1774531 0.83 CYP2C19 (0.61) HRH4HRH3HRH2CYP1A2ALDH1A1
SCHEMBL12497703 0.82 HRH4 (0.57) HRH4HRH3HRH2CYP1A2ALDH1A1
SCHEMBL27267881 0.82 HRH4 (0.54) HRH4HRH3HRH2CYP1A2ALDH1A1
SCHEMBL4953668 0.81 HRH4 (0.55) HRH4HRH3HRH2CYP1A2ALDH1A1
SCHEMBL4953660 0.81 HRH4 (0.55) HRH4HRH3HRH2CYP1A2ALDH1A1
SCHEMBL1774811 0.81 CYP1A2 (0.57) HRH4HRH3HRH2CYP1A2ALDH1A1
SCHEMBL807737 0.81 HRH4 (0.59) HRH4HRH3HRH2CYP1A2ALDH1A1
SCHEMBL27363158 0.79 HRH4 (0.51) HRH4HRH3HRH2CYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966162-B1 PYRIMIDINE DERIVATIVES ZIARCO PHARMA LTD (GB) 2017-03-15 EP disclosed
EP-1966162-B1 PYRIMIDINE DERIVATIVES ZIARCO PHARMA LTD (GB) 2017-03-15 EP disclosed
CN-101341134-B Pyrimidine derivatives PFIZER LTD 2013-05-01 CN disclosed
US-7943628-B2 Pyrimidine derivatives PFIZER LIMITED (GB) 2011-05-17 US disclosed
US-7943628-B2 Pyrimidine derivatives PFIZER LIMITED (GB) 2011-05-17 US disclosed
US-7943628-B2 Pyrimidine derivatives PFIZER LIMITED (GB) 2011-05-17 US disclosed
EP-1966162-A2 PYRIMIDINE DERIVATIVES Pfizer Limited (GB) 2008-09-10 EP disclosed
US-20070185075-A1 Pyrimidine derivatives PFIZER LIMITED 2007-08-09 US disclosed
US-20070185075-A1 Pyrimidine derivatives PFIZER LIMITED 2007-08-09 US disclosed
US-20070185075-A1 Pyrimidine derivatives PFIZER LIMITED 2007-08-09 US disclosed
WO-2007072163-A2 PYRIMIDINE DERIVATIVES PFIZER LIMITED (GB) 2007-06-28 WO disclosed
WO-2007072163-A2 PYRIMIDINE DERIVATIVES PFIZER LIMITED (GB) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185075-A1 Pyrimidine derivatives TYMS, DPYD, TYMP HRH4 184/4885HRH3 187/4885HRH2 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.